Evonik Industries AG (EVK) Earnings Call Transcripts
Evonik Industries AG's Latest Earnings Call - June 10, 2026
In the Q2 2026 earnings call, Evonik Industries AG (EVK:DE) reported a revenue of €3.2 billion, a 5% increase year-over-year, and an adjusted EBITDA of €550 million, reflecting a 10% margin. Management maintained its guidance for the full fiscal year, expecting revenue growth of 4-6% and EBITDA margins to remain stable. Key highlights included advancements in innovation, particularly in sustainable solutions and biotechnology, which are expected to drive future growth and resilience amid global supply chain challenges.
Reported metrics
| Metric | Value |
|---|---|
| Revenue | €3.2B (beat) |
| Adjusted EBITDA | €550M (inline) |
| R&D Expenses | €418M (inline) |
| Next-Generation Solutions Revenue Share | 48% (positive) |
| Expected Additional Revenue from Innovation | €1.5B (positive) |
| Investment in Biotechnology | €80M (positive) |
Guidance from management
Evonik maintained its revenue growth guidance of 4-6% for the fiscal year 2026, with expectations for EBITDA margins to remain stable, reflecting confidence in operational resilience despite market challenges.
What management said
[Interpreted] Well, it's a great studio, and I had the opportunity with an internal program, a dialogue with the Board of Directors to have the experience of the studio already once. Thank you for the invitation once more.
[Interpreted] Well, internally, we practiced a little bit in order to be sure that it works all okay and you are in charge of innovation on the Board of Directors, but also for Customer Solutions, it's a very important segment for the region Americas. It's not a small region either. What about your personnel and individual resilience when I look at your workload?
What analysts pressed on
Analysts expressed concerns regarding the potential impact of geopolitical tensions on supply chains and the pace of innovation adoption in a competitive market. There were questions about the scalability of new technologies and the effectiveness of partnerships in driving growth.
Main topics on the call
- Innovation Focus — Evonik emphasized its commitment to innovation, stating, "Our innovation power turns into a competitive advantage for our customers." The company is prioritizing R&D investments, maintaining a stable R&D ratio of 3%, whi...
- Sustainability Initiatives — Management highlighted the importance of sustainability, noting that "the revenue share of our next-generation solutions rose from 45% to 48%" between 2024 and 2025. This shift is part of Evonik's strategy to align growt...
- Resilience in Supply Chains — The ongoing geopolitical tensions have prompted Evonik to enhance its supply chain resilience. Kjeldsen stated, "A resilient company is one that can absorb shocks, adapt quickly to changing conditions, and recover effici...
- Financial Guidance — Management maintained its revenue growth guidance of 4-6% for FY 2026, indicating confidence in operational performance despite market volatility. They expect EBITDA margins to remain stable, reflecting operational robus...
Read the full Evonik Industries AG transcript (June 10, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.
About Evonik Industries AG
Evonik Industries AG (EVK) is a publicly listed company in the Chemicals industry, within the Materials sector. It trades on XTRA and is based in DE. EarningsCalls.dev maintains a free, full-text archive of its earnings call transcripts — 32 calls on record spanning March 4, 2020 to August 4, 2026. Every transcript is split into speaker-by-speaker segments with headline metrics, free to read or available through our REST API.
Earnings Call History
EarningsCalls.dev has 32 Evonik Industries AG earnings call transcripts on record, spanning March 4, 2020 to August 4, 2026. Based on this history, Evonik Industries AG reports quarterly. The most recent call on file is dated August 4, 2026. The full list is below — each row opens the complete, free-to-read transcript.